DCFBC

DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer[1].

Product Specifications

CAS Number

[564482-79-7]

UNSPSC

12352005

Target

PSMA

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dcfbc.html

Smiles

OC(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CSCC1=CC=C(C=C1)F)=O)=O

Molecular Formula

C16H19FN2O7S

Molecular Weight

402.39

References & Citations

[1]Mease RC, et al. N-[N-[ (S) -1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008 May 15;14 (10) :3036-43.